{"nctId":"NCT00680017","briefTitle":"30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease","startDateStruct":{"date":"2008-06"},"conditions":["Dyslipidemia","Kidney Disease"],"count":280,"armGroups":[{"label":"ABT-335 plus rosuvastatin","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-335 plus rosuvastatin"]},{"label":"Rosuvastatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rosuvastatin"]}],"interventions":[{"name":"ABT-335 plus rosuvastatin","otherNames":["fenofibric acid and rosuvastatin"]},{"name":"Rosuvastatin","otherNames":["rosuvastatin, Crestor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Dyslipidemic participants with Chronic Kidney Disease Stage 3\n* For entry into the Treatment Phase (Visit 3), the participant satisfied the following laboratory criteria (measured at the Screening Visit\\[s\\]):\n\n  * Estimated glomerular filtration rate between 30 and 59 mL/min/1.73 m2 (Chronic Kidney Disease Stage 3) by simplified 4 variable Modification of Diet in Renal Disease formula (this includes a 10 percent variation in the upper limit of estimated glomerular filtration rate that was allowed for the enrollment of participants to account for variability in the creatinine assay).\n  * Fasting lipid results following greater than or equal to 12-hour fasting period:\n* Triglycerides level greater than or equal to 150 mg/dL,\n* High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50 mg/dL for females, and\n* Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL Exclusion Criteria\n* Participants with certain chronic or unstable medical conditions.\n* Participants with unstable dose of medications or receiving coumarin anticoagulants, systemic cyclosporine, or certain other medications.\n* Pregnant or lactating women, or women intending to become pregnant.\n* Participants with diabetes mellitus that is poorly controlled.\n* Participants of Asian ancestry (having Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian origin).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Median Percent Change in Triglycerides From Baseline to Week 8.","description":"Triglycerides were measured in milligrams/deciliter.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.0","spread":null},{"groupId":"OG001","value":"-22.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in High-Density Lipoprotein Cholesterol From Baseline to Week 8.","description":"High-density lipoprotein cholesterol (HDL-C) was measured in milligrams/deciliter (mg/dL).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":"1.44"},{"groupId":"OG001","value":"7.8","spread":"1.43"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":140},"commonTop":["Oedema Peripheral","Headache","Cough","Diarrhoea","Glomerular Filtration Rate Decreased"]}}}